id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-2033-0008,FDA,FDA-2024-D-2033,Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Extension of Comment Period,Notice,Extension of Comment Period,2025-01-17T05:00:00Z,2025,1,2025-01-17T05:00:00Z,,2026-02-06T19:55:56Z,2025-01179,0,0,09000064868e2fb8
FDA-2024-D-2033-0005,FDA,FDA-2024-D-2033,Comment from Alliance for Regenerative Medicine,Other,Request for Extension,2025-01-07T05:00:00Z,2025,1,2025-01-07T05:00:00Z,,2025-01-07T17:43:05Z,,0,0,09000064868a01b6